JP2015500797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500797A5 JP2015500797A5 JP2014541481A JP2014541481A JP2015500797A5 JP 2015500797 A5 JP2015500797 A5 JP 2015500797A5 JP 2014541481 A JP2014541481 A JP 2014541481A JP 2014541481 A JP2014541481 A JP 2014541481A JP 2015500797 A5 JP2015500797 A5 JP 2015500797A5
- Authority
- JP
- Japan
- Prior art keywords
- glycoprotein
- soluble
- cell
- fusion protein
- effector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013135 CD52 Antigen Human genes 0.000 claims description 150
- 108010065524 CD52 Antigen Proteins 0.000 claims description 150
- 210000004027 cell Anatomy 0.000 claims description 107
- 108020001507 fusion proteins Proteins 0.000 claims description 53
- 102000037865 fusion proteins Human genes 0.000 claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 108091033319 polynucleotide Proteins 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 33
- 239000002157 polynucleotide Substances 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 28
- 230000003915 cell function Effects 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 150000001720 carbohydrates Chemical class 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 21
- 206010040047 Sepsis Diseases 0.000 claims description 21
- 230000004054 inflammatory process Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000006143 cell culture medium Substances 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 238000007877 drug screening Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 4
- 229940124606 potential therapeutic agent Drugs 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 claims description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000013074 reference sample Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560254P | 2011-11-15 | 2011-11-15 | |
| US61/560,254 | 2011-11-15 | ||
| US201261705633P | 2012-09-26 | 2012-09-26 | |
| US61/705,633 | 2012-09-26 | ||
| PCT/AU2012/001411 WO2013071355A1 (en) | 2011-11-15 | 2012-11-15 | Soluble mediator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500797A JP2015500797A (ja) | 2015-01-08 |
| JP2015500797A5 true JP2015500797A5 (enExample) | 2015-08-06 |
| JP6004594B2 JP6004594B2 (ja) | 2016-10-12 |
Family
ID=48428838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541481A Expired - Fee Related JP6004594B2 (ja) | 2011-11-15 | 2012-11-15 | 可溶性メディエーター |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9585969B2 (enExample) |
| EP (2) | EP3456338B1 (enExample) |
| JP (1) | JP6004594B2 (enExample) |
| KR (1) | KR102134326B1 (enExample) |
| CN (1) | CN103930123B (enExample) |
| AU (1) | AU2012339618B2 (enExample) |
| BR (1) | BR112014011758A2 (enExample) |
| CA (2) | CA2852133A1 (enExample) |
| ES (2) | ES2703236T3 (enExample) |
| HR (1) | HRP20182001T1 (enExample) |
| LT (1) | LT2750690T (enExample) |
| MX (1) | MX357655B (enExample) |
| PT (1) | PT2750690T (enExample) |
| RU (1) | RU2660580C2 (enExample) |
| SG (1) | SG11201402310SA (enExample) |
| WO (1) | WO2013071355A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2750690T (lt) * | 2011-11-15 | 2019-01-10 | The Walter And Eliza Hall Institute Of Medical Research | Tirpus mediatorius |
| WO2013185165A1 (en) * | 2012-06-14 | 2013-12-19 | The Walter And Eliza Hall Institute Of Medical Research | Cd-52 antibodies and their use in determining and enhancing an immune response in a subject |
| US9778269B2 (en) * | 2012-11-15 | 2017-10-03 | The Walter And Eliza Hall Institute Of Medical Research | Method of treating sepsis by administering a soluble CD52 glycoprotein |
| US20180002435A1 (en) * | 2015-01-26 | 2018-01-04 | Cellectis | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| AU2019201584B1 (en) * | 2019-03-07 | 2019-12-05 | Macquarie University | Immunosuppressive glycoforms of soluble cd52 |
| EP3935073A4 (en) * | 2019-03-07 | 2022-11-23 | The Walter and Eliza Hall Institute of Medical Research | IMMUNOSUPPRESSIVE GLYCOFORMS OF SOLUBLE CD52 |
| CN111909235B (zh) * | 2019-05-08 | 2022-12-06 | 广西大学 | 一种利用Trans Well小室分离精子释放蛋白的方法 |
| WO2021011678A1 (en) * | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| CN114315937B (zh) * | 2022-01-13 | 2024-08-09 | 甘肃智仑新材料科技有限公司 | 一种压驱、压裂用生物质纳米增渗剂及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8317576D0 (en) | 1983-06-29 | 1983-08-03 | Shaw A S W | Consumer tobacco products |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| US4904475A (en) | 1985-05-03 | 1990-02-27 | Alza Corporation | Transdermal delivery of drugs from an aqueous reservoir |
| GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
| US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
| US4927408A (en) | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
| US5792294A (en) | 1995-11-16 | 1998-08-11 | Otis Elevator Company | Method of replacing sheave liner |
| AU9399501A (en) * | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| ATE443259T1 (de) | 2001-09-20 | 2009-10-15 | Univ Texas | Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests |
| RU2369636C2 (ru) * | 2003-05-23 | 2009-10-10 | Уайт | Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения |
| RU2403262C2 (ru) * | 2003-06-11 | 2010-11-10 | Уайт | Выделенный полипептид ib альфа гликопротеина тромбоцитов человека, слитый белок, молекула днк (варианты), экспрессирующий вектор (варианты), клетка (варианты), способ экспрессии полипептида, способ экспрессии слитого белка, фармацевтическая композиция (варианты), способ ингибирования прикрепления клетки крови к биологической ткани в биологической системе, способ ингибирования прикрепления белка к биологической ткани в биологической системе и способ лечения нарушения |
| US20050069958A1 (en) * | 2003-09-26 | 2005-03-31 | Mills Rhonda A. | Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte |
| EP1696956A4 (en) * | 2003-12-22 | 2007-08-01 | Genzyme Corp | ANTI-CD52 ANTIBODIES AND TREATMENT OF DIABETES |
| WO2008028229A1 (en) | 2006-09-05 | 2008-03-13 | The Walter And Eliza Hall Institute Of Medical Research | Methods of identifying markers |
| CA2726341C (en) | 2008-05-30 | 2018-12-18 | University Of Louisville Research Foundation, Inc. | Human facilitating cells |
| CA2791866A1 (en) * | 2010-03-04 | 2011-09-09 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to cd52 |
| LT2750690T (lt) | 2011-11-15 | 2019-01-10 | The Walter And Eliza Hall Institute Of Medical Research | Tirpus mediatorius |
-
2012
- 2012-11-15 LT LTEP12850386.9T patent/LT2750690T/lt unknown
- 2012-11-15 US US14/351,501 patent/US9585969B2/en not_active Expired - Fee Related
- 2012-11-15 BR BR112014011758A patent/BR112014011758A2/pt not_active Application Discontinuation
- 2012-11-15 AU AU2012339618A patent/AU2012339618B2/en not_active Ceased
- 2012-11-15 EP EP18193427.4A patent/EP3456338B1/en active Active
- 2012-11-15 ES ES12850386T patent/ES2703236T3/es active Active
- 2012-11-15 RU RU2014122847A patent/RU2660580C2/ru active
- 2012-11-15 HR HRP20182001TT patent/HRP20182001T1/hr unknown
- 2012-11-15 KR KR1020147016049A patent/KR102134326B1/ko not_active Expired - Fee Related
- 2012-11-15 CN CN201280056027.1A patent/CN103930123B/zh not_active Expired - Fee Related
- 2012-11-15 JP JP2014541481A patent/JP6004594B2/ja not_active Expired - Fee Related
- 2012-11-15 ES ES18193427T patent/ES2814300T3/es active Active
- 2012-11-15 PT PT12850386T patent/PT2750690T/pt unknown
- 2012-11-15 EP EP12850386.9A patent/EP2750690B1/en not_active Not-in-force
- 2012-11-15 CA CA2852133A patent/CA2852133A1/en not_active Abandoned
- 2012-11-15 MX MX2014005688A patent/MX357655B/es active IP Right Grant
- 2012-11-15 SG SG11201402310SA patent/SG11201402310SA/en unknown
- 2012-11-15 WO PCT/AU2012/001411 patent/WO2013071355A1/en not_active Ceased
-
2013
- 2013-03-25 CA CA2890797A patent/CA2890797C/en active Active
-
2016
- 2016-12-19 US US15/384,137 patent/US10010582B2/en active Active
-
2018
- 2018-05-09 US US15/975,591 patent/US10328124B2/en not_active Expired - Fee Related
- 2018-12-12 US US16/218,287 patent/US10413589B2/en not_active Expired - Fee Related
-
2019
- 2019-08-21 US US16/547,322 patent/US11123403B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500797A5 (enExample) | ||
| Nasr et al. | Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule | |
| Litwinoff et al. | Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway | |
| Wu et al. | Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy | |
| Li et al. | A galectin-9–driven CD11chigh decidual macrophage subset suppresses uterine vascular remodeling in preeclampsia | |
| Shi et al. | Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis | |
| EP1469879B1 (en) | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders | |
| JP2013503204A (ja) | Ｂ７−ｈ４融合タンパク質およびその使用方法 | |
| RU2014122847A (ru) | Растворимый медиатор | |
| JP2012159356A (ja) | 敗血症診断用組合せマーカー | |
| EP3185885B1 (en) | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders | |
| Son et al. | Regression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus | |
| Audemard-Verger et al. | Recruitment of CXCR3+ T cells into injured tissues in adult IgA vasculitis patients correlates with disease activity | |
| BR112020013531A2 (pt) | Uso de anticorpo anti-il-6, por exemplo, clazakizumab para dessensibilização de receptores de transplante de órgãos sólidos e/ou para prevenir, estabilizar ou reduzir rejeição mediada por anticorpos (abmr) | |
| Sabatino Jr et al. | Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity | |
| JP2021534195A (ja) | 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置 | |
| KR20170052526A (ko) | 다발성 경화증에 대한 병용 치료 | |
| US20130017206A1 (en) | Mcam modulation and uses thereof | |
| AU2023336565A1 (en) | Medical use of ccr8 antibodies and dosing schedule | |
| US20140271694A1 (en) | Antigen-specific methods of diagnosing and/or treating myocarditis or inflammatory cardiomyopathy | |
| Xia et al. | Selective expression and cellular localization of pro‐inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain–Barré syndrome | |
| EP2782599B1 (en) | Administration of alpha4beta7 hetero-dimer-specific antibody | |
| WO2003059245A2 (en) | Method of treating asthma | |
| CA2759231A1 (en) | Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients | |
| Cao et al. | Elevated serum levels of visfatin in patients with henoch-schönlein purpura |